Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Drug

Sunshine Guojian’s SSGJ-627 Gains NMPA Approval for Ulcerative Colitis Trial

Fineline Cube Apr 7, 2025

China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, (SHA: 688336) a subsidiary of 3SBio Inc. (HKG:...

Company Drug

Sarepta and Roche Seek to Resume Elevidys Trials After EMA Halt

Fineline Cube Apr 7, 2025

The European Medicines Agency (EMA) may lift the temporary hold on certain Phase III studies...

Company Drug

Bayer’s Vividion Therapeutics Starts Phase I Study for RAS-PI3Kα Inhibitor

Fineline Cube Apr 7, 2025

German pharmaceutical giant Bayer’s (ETR: BAYN) wholly owned subsidiary Vividion Therapeutics, Inc. has announced the...

Company Deals

ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform

Fineline Cube Apr 7, 2025

South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement...

Company

BeiGene Halts Ociperlimab Clinical Program for Lung Cancer

Fineline Cube Apr 7, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist formerly known as...

Company Deals

Eli Lilly Secures Global License for Sangamo’s STAC-BBB Gene Therapy Technology

Fineline Cube Apr 7, 2025

US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has entered into a licensing agreement...

Company Medical Device

MicroPort Endovascular’s Talos Stent Approved in Brazil for Aortic Dissection

Fineline Cube Apr 7, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Company Drug

Fujian Kerui’s Generic Sirolimus Gel Approved by China’s NMPA

Fineline Cube Apr 7, 2025

China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer’s (NYSE: PFE)...

Company Deals

Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies

Fineline Cube Apr 3, 2025

US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...

Company Deals Medical Device

Yuewei Medtech Secures RMB100 Million in Series A++ Funding for Cardiac Device Development

Fineline Cube Apr 3, 2025

Beijing Yuewei Medical Technology Co., Ltd, a medical device company specializing in coronary heart disease,...

Company

Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals

Fineline Cube Apr 3, 2025

Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8...

Company Deals

GE Healthcare Partners with Probo Medical to Distribute Ultrasound Devices

Fineline Cube Apr 3, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has entered...

Company Drug

Henlius Biotech’s HLX04-O Shows Positive Results in wAMD Phase III Trial

Fineline Cube Apr 3, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced positive results from the Phase III...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC Receives Clinical Trial Approval in China

Fineline Cube Apr 3, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that it has received clinical trial...

Company Deals

Sinovac Partners with CPMA to Advance Vaccine Preventable Disease Initiatives

Fineline Cube Apr 3, 2025

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has entered into a strategic memorandum of understanding (MoU)...

Company Drug

Novartis’ Vanrafia Gets FDA Accelerated Approval for IgAN

Fineline Cube Apr 3, 2025

Switzerland-based Novartis (NYSE: NVS) announced that it has received accelerated approval from the US Food...

Company Deals

Sanofi and Cathay Capital Launch RMB 2 Billion Pharma Innovation Fund in China

Fineline Cube Apr 3, 2025

The Sanofi Cathy Capital Pharmaceutical Innovation Fund, a joint venture between French pharmaceutical giant Sanofi...

Company Medical Device

Sihuan Pharma’s Polycaprolactone Microsphere Filler Gains NMPA Approval

Fineline Cube Apr 3, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has received Category III...

Company Deals Drug

Shionogi Partners with Link Medical for Cefiderocol Development in Australia and New Zealand

Fineline Cube Apr 3, 2025

Japan-based Shionogi Co., Ltd. has entered into an exclusive licensing agreement with Link Medical Products...

Company Deals

WuXi XDC Partners with MABSOFT to Advance Innovative ADC Development

Fineline Cube Apr 3, 2025

China-based WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi...

Posts pagination

1 … 119 120 121 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.